Assembly Biosciences (ASMB) Total Debt (2010 - 2011)

Assembly Biosciences (ASMB) posted quarterly Total Debt of $1.3 million for Q2 2011, down 21.91% quarter-over-quarter from $1.7 million in Q4 2010.

Assembly Biosciences (ASMB) Total Debt (2010 - 2011) Analysis & Trends

Assembly Biosciences' Total Debt history runs 2 years deep, the most recent figure standing at $1.3 million for Q2 2011.

In Q2 2011, Total Debt changed N/A year-over-year to $1.3 million; the TTM figure through Jun 2011 stood at $1.3 million (changed N/A YoY), while the FY2010 annual figure was $1.7 million, changed N/A from the prior year.
Total Debt for Q2 2011 stood at $1.3 million, down from $1.7 million in the prior quarter.
The five-year high for Total Debt was $1.7 million in Q4 2010, with the low at $1.3 million in Q2 2011.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.07 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	9.34 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	546.77 Mn
10	Assembly Biosciences	670.88 Mn	350.52 Mn	-	-

Download Data

Date	Value
Jun 30, 2011	1.32 Mn
Dec 31, 2010	1.69 Mn